首页 | 官方网站   微博 | 高级检索  
     

复方红衣补血口服液联合乳酸亚铁治疗妊娠期缺铁性贫血的临床研究
引用本文:张彦芬,高大,易媛媛,赵荣伟. 复方红衣补血口服液联合乳酸亚铁治疗妊娠期缺铁性贫血的临床研究[J]. 现代药物与临床, 2019, 34(8): 2449-2453
作者姓名:张彦芬  高大  易媛媛  赵荣伟
作者单位:内蒙古医科大学附属医院 血液科,内蒙古 呼和浩特,010050;内蒙古医科大学附属医院 妇产科,内蒙古 呼和浩特,010050
基金项目:内蒙古自治区卫生计生科研计划项目(201701069)
摘    要:目的探讨复方红衣补血口服液联合乳酸亚铁治疗妊娠期缺铁性贫血的临床疗效。方法选取2017年1月—2018年6月内蒙古医科大学附属医院收治的妊娠期缺铁性贫血患者94例,随机分为对照组和治疗组,每组各47例。对照组口服乳酸亚铁片,2片/次,3次/d。治疗组在对照组的基础上口服复方红衣补血口服液,10mL/次,3次/d。两组患者均治疗4周。观察两组患者临床疗效,同时比较治疗前后两组患者临床症状缓解时间、妊娠结局及外周血红细胞参数、网织红细胞参数和铁代谢指标。结果治疗后,对照组临床治愈率为65.96%,显著低于治疗组的82.98%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组临床症状缓解时间均显著短于对照组(P0.05)。治疗后,治疗组剖宫产率和低体质量儿出生率显著低于对照组(P0.05)。治疗后,两组患者外周血未成熟网织红细胞比率(IRF)、可溶性转铁蛋白受体(sTFR)和s TFR/血清铁蛋白(SF)水平显著下降(P0.05),血红细胞计数(RBC)、血红蛋白(Hb)、红细胞平均体积(MCV)、红细胞平均血红蛋白(MCH)、单个网织红细胞平均血红蛋白浓度(CHCMr)和SF水平显著升高(P0.05),且治疗组外周血这些指标水平的改善幅度明显(P0.05)。结论复方红衣补血口服液联合乳酸亚铁治疗妊娠期缺铁性贫血可以促进铁代谢,改善红细胞的发育,缓解临床症状,提高临床治愈率。

关 键 词:复方红衣补血口服液  乳酸亚铁片  妊娠期缺铁性贫血  未成熟网织红细胞比率  红细胞平均体积  可溶性转铁蛋白受体
收稿时间:2019-01-12

Clinical study on Compound Hongyi Buxue Oral Liquid combined with ferrous lactate in treatment of iron deficiency anemia in pregnancy
ZHANG Yan-fen,GAO D,YI Yuan-yuan and ZHAO Rong-wei. Clinical study on Compound Hongyi Buxue Oral Liquid combined with ferrous lactate in treatment of iron deficiency anemia in pregnancy[J]. Drugs & Clinic, 2019, 34(8): 2449-2453
Authors:ZHANG Yan-fen  GAO D  YI Yuan-yuan  ZHAO Rong-wei
Affiliation:Department of Hematology, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010050, China,Department of Hematology, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010050, China,Department of Obstetrics and Gynecology, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010050, China and Department of Obstetrics and Gynecology, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010050, China
Abstract:Objective To explore the clinical effect of Compound Hongyi Buxue Oral Liquid combined with ferrous lactate in treatment of iron deficiency anemia in pregnancy. Methods Patients (94 cases) with iron deficiency anemia in pregnancy in the Affiliated Hospital of Inner Mongolia Medical University from January 2017 to June 2018 were randomly divided into control and treatment groups, and each group had 47 cases. Patients in the control group were po administered with Ferrous Lactate Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Compound Hongyi Buxue Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptoms remission time, pregnancy outcome, erythrocyte, reticulocyte parameters and iron metabolism in peripheral blood in two groups before and after treatment were compared. Results After treatment, the clinical cure rate in the control group was 65.96%, which was significantly lower than 82.98% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the clinical symptoms remission time in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the cesarean section rate and birth rate of low weight infants in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the IRF, sTFR, and sTFR/SF levels of peripheral blood in two groups were significantly decreased (P<0.05), but RBC, Hb, MCV, MCH, CHCMr, and SF of peripheral blood were significantly increased (P<0.05), and thses peripheral blood indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusions Compound Hongyi Buxue Oral Liquid combined with ferrous lactate in treatment of iron deficiency anemia in pregnancy can promote iron metabolism, improve the development of red blood cells, alleviate clinical symptoms and improve the clinical cure rate.
Keywords:Compound Hongyi Buxue Oral Liquid  Ferrous Lactate Tablets  iron deficiency anemia in pregnancy  IRF  MCV  sTFR
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号